News Cost of AZ’s new Cambridge HQ ‘has more than doubled’ The cost of AstraZeneca’s new R&D hub and corporate headquarters in Cambridge has swelled to £750 million, more than twice the original estimate, says a report in The Times.
News First malaria drug for newborns and young infants cleared A new formulation of Novartis' antimalarial Coartem has become the first medicine to be approved for use in very young children.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face